Matinas BioPharma (MTNB) Misses Q3 EPS by 1c; Reports Cash and Cash Equivalents of $53.8M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Matinas BioPharma Reports Third Quarter 2021 Financial Results and Operational Highlights
November 8, 2021 6:35 AM ESTPositive efficacy and safety data announced from first two cohorts of patients in ongoing EnACT study of MAT2203 (oral amphotericin B) for treatment of cryptococcal meningitis; DSMB unanimously recommended progression to second half of study
Dosing initiated in Phase 1 study of potential first oral aminoglycoside antibiotic drug MAT2501 (oral amikacin)
Accomplished biotechnology executive, Kathryn Penkus Corzo, joined Companys Board of Directors
Management to host conference call today, Monday, November 8th, at 8:30 a.m. ET
BEDMINSTER, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) --... More
